Digestive Health Newsletter

Bring Out the Best in Your Healthcare Team

Brooks D. Cash, MD

Volume 17, 
December 01, 2009

by Brooks D. Cash, MD

Brooks Cash, MD Brooks D. Cash, MD, FACP, FACG, AGAF, is the Integrated Chief of Medicine at the National Naval Medical Center in Bethesda, MD and the Walter Reed Army Medical Center in Washington, D.C. His gastroenterology research has had an emphasis on functional GI disorders, colon cancer screening, and outcomes research. Dr. Cash is an Associate Professor of Medicine at the Uniformed Services University of the Health Sciences, where he has held a faculty position since 1996.

Dr. Cash received his undergraduate degree in business administration with honors (Finance) from the University of Texas in Austin. He then earned his medical degree from the Uniformed Services University of Health Sciences in Bethesda. He completed his internship and residency at the National Naval Medical Center in Bethesda, MD, where he went on to complete a fellowship in gastroenterology.

Dr. Cash is a Diplomat of the American Board of Gastroenterology. He is a Fellow of the American College of Gastroenterology and the American Gastroenterological Association and is a member of the American Society of Gastroenterology. He has authored multiple articles and book chapters and serves as a reviewer for numerous internal medicine and gastroenterological medical journals.

Table of Contents

Introduction

You have probably found that your circle of healthcare providers has expanded since you were first diagnosed with inflammatory bowel disease (IBD). This newsletter will help you understand the role of each member of your healthcare team, find good healthcare providers and build good relationships with them, coordinate your care, and get a second opinion if you need one. By following just a few simple steps, you will become the captain of your healthcare team and ensure that you get the care you need and deserve.

Back to Top

Who's on First?

As the number of different healthcare providers in your rolodex grows, it helps to have a clear understanding of everyone's role. Knowing who to call and when to call them will save you time, energy, and delays in care. Here is a list of key healthcare providers that may be involved in your care. Click on each name for more details.

 

    · Primary Care Provider

    · Gastroenterologist

    · Colorectal Surgeon

    · Physician Assistant

    · Nurse Practitioner

    · Registered Dietitian

    · Pharmacist

    · Mental Health Professional

 

Back to Top

How do I find good healthcare providers?

When it's time for a new car or major appliance for your home, you probably spend time researching your options and comparing notes with friends and family. Finding a healthcare provider should be no different – after all, it's your health that's at stake! It's often easiest to start by getting recommendations from friends, coworkers, and family, as well as acquaintances who may also have IBD.

One very helpful source for information regarding health care services is your local chapter of the Crohn's and Colitis Foundation of America (CCFA) – the CCFA website has links to chapters by state. Professional organizations, like the American Medical Association (for all medical doctors), the Gastroenterological Association or the American College of Gastroenterology (for gastroenterologists), the American Board of Colon and Rectal Surgery (for surgeons), and the American Dietetic Association (for registered dietitians) can also be good sources for referrals. Keep in mind that, depending on your health insurance, your choices may be limited to healthcare providers who participate in your plan.

Once you have a list of options, ask questions:

  • Do you accept my health insurance?
  • At which hospital(s) do you have privileges?
  • Where are you located?
  • What are your office hours?
  • How long does it usually take to get a routine appointment?

Back to Top

How can I build a good relationship with my healthcare provider?

Having a good relationship with your healthcare provider is an important component of your healthcare, whether or not you have a chronic disease. Here are some tips to get you off on the right foot:

 

     

  • Be honest – about your medical history and whether or not you are taking your medication as prescribed. You might be tempted to say what you think your healthcare provider wants to hear or that you're feeling better than you truly are. But the only way your healthcare provider can give you personalized treatment is if he or she has complete and accurate information about you and your condition
  •  

     

  • Be informed – communication between you and your healthcare provider should be a two–way street. The more you know about IBD, the more you can play an active role on your healthcare team. To that end, you should be sure to read your medication labels and instructions, understand what your medications are for, and know when you will need to refill your prescriptions.
  •  

     

  • Be prepared – the better prepared you are, the more you will be able to accomplish during each appointment with your healthcare provider. Try keeping a list of your questions, symptoms, and concerns, and bringing the list with you to your appointment. It often helps to bring a trusted family member or close friend along – someone who can help ask questions, take notes, and remember what was said. Be sure to know the names and dosages of all of your prescriptions and over–the–counter medications. You can use a Mind Your Meds chart to help you keep track.
  •  

     

  • Ask questions – when it comes to your health, no question is a dumb question. While it's true that healthcare providers are often very busy and tend to be in a hurry, part of their job is to spend time with you in order to give you the information you need. Start with your most important questions first, in case you run out of time. Try to be specific, asking for clarification about anything you don't understand. It's often helpful to repeat the answers back in your own words, to make sure there are no misunderstandings. Click here for specific questions to ask about your medication, and click here for specific questions to ask about surgery. For more information about IBD medication, refer to the newsletter, "Mind Your Meds – An Updated Review," by Dr. Nisa Kubiliun and Dr. Jamie S. Barkin. For more information about surgery, refer to the newsletter, "IBD and Colorectal Surgery," by Dr. Steven Wexner and Dr. Yair Edden.
  •  

     

  • Keep your appointments or call to cancel before the last minute – that's common courtesy. Doctors' offices are busy places and schedules are often booked up for several weeks, so it may be difficult to quickly get another appointment when you cancel. Plus, missing an appointment can convey the impression that your health is not a priority.
  •  

     

  • Understand that sometimes a long wait in the waiting room may be inevitable – most healthcare professionals have very little control over their schedules. A clinic's appointment schedule often leaves little wiggle room for very complicated patients, computer problems, staff turnover, or other issues that are beyond your healthcare provider's control. The result is that, on occasion, your doctor may be running late.
  •  

 

Back to Top

How can I make sure all of my healthcare providers are on the same page?

It's a good idea to keep your PCP's contact information handy. That way, whenever you see a specialist or undergo testing by another healthcare provider, you can ask that the results be sent to your PCP (you may need to sign a release form). You can also make sure your PCP has contact information for the specialists you have seen, along with the dates of each appointment and any tests that were performed.

Back to Top

When should I think about getting a second opinion?

It's a good idea to get a second opinion if you receive a serious diagnosis or need surgery. Be sure to let your healthcare provider know your intent. Second opinions are standard practice, and a good doctor will not be offended. In fact, he or she should be able to give you the name of other reliable doctors with whom to consult. When you go for the second opinion, bring all relevant records and test results, and be up front about the fact that you are looking for a second opinion. Once you have a second opinion, compare similarities and differences in order to make the most educated decisions regarding your care. You may also want to discuss these similarities and differences with family/friends and other members of your health care team.

Back to Top

Conclusion

Your healthcare team is a very important part of your life – one that is there to help you manage your IBD and keep your symptoms in check. When you become an active member of that team, you will be able to participate fully in all of the decisions related to your care. It's both your right and your responsibility!

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter